Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses

Blood

Volumn 105, Issue 9, 2005, Pages 3596-3604

  Muraro, Sara ^b   Bondanza, Attilio ^b   Bellone, Matteo ^b   Greenberg, Philip D ^b   Bonini, Chiara ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN IDIOTYPE LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1 FUSION PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; B CELL LYMPHOMA; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG SYNTHESIS; EFFECTOR CELL; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE REARRANGEMENT; HUMORAL IMMUNITY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 18244394030     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2890     Document Type: Article

References (66)

1. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-522.
2. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol. 1987;139:2825-2833.
3. George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol. 1988;141:2168-2174.
4. Chakrabarti D, Ghosh SK. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor, II: characterization of anti-idiotypic CTL lines and clones. Cell Immunol. 1992;144:443-454.
5. Cao W, Myers-Powell BA, Braciale TJ. Recognition of an immunoglobulin VH epitope by influenza virus-specific Class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med. 1994;179:195-202.
6. Abe A, Emi N, Taji H, Kasai M, Kohno A, Saito H. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Gene Ther. 1996;3:988-993.
7. Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood. 2000;95:1342-1349.
8. Kwak LW, Campbell MJ, Czerwinski D, Hart S, Miller RA, Levy R. Induction of immune response impatients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
9. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
10. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A. 1994;91:5700-5704.
11. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica. 2002;87:989-1001.
12. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol. 2003;123:770-781.
13. Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80:1502-1510.
14. Brown SL, Miller RA, Horning SJ, et al. Treatment of B-cell lymphoma with anti-adiotype antibodies alone and in combination with alpha interferon. Blood. 1989;73:651-661.
15. Clearly ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell. 1986;44:97-106.
16. Meeker T, Lowder J, Clearly ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies, N Engl J Med. 1985;312:1658-1665.
17. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. J Immunol. 1988;141:3227-3233.
18. Rosenberg SA. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin. 1999;49:70-73, 65.
19. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995;145:167-177.
20. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
21. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
22. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 1992;58:143-175.
23. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD, Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science. 1992;257:238-241.
24. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-355.
25. Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol. 1985;135:2895-2903.
26. Greenberg PD. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2 cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol. 1986;136:1917-1922.
27. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
28. Kronenberger K, Dieckmann A, Selmayr M, et al. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. Blood. 2002;99:1327-1331.
29. Chen HW, Lee YP, Chung YF, et al. Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy. Int Immunol. 2003;15:427-435.
30. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985;161:1122-1134.
31. + T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res. 2003;63:1040-1045.
32. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol. 1997;159:1885-1892.
33. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med. 1996;2:1038-1041.
34. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1 B augments antitumor immune responses induced by protein and DNA vaccines. J Immunol. 1996;157:5503-5511.
35. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. J Immunol. 1994;153:4775-4787.
36. Tao H, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature. 1993;362:755-758.
37. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
38. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-273.
39. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
40. + T cells. J Immunol. 2001;166:5250-5257.
41. Lewis V, Green SA, Marsh M, Vihko P, Helenius A, Mellman I. Glycoproteins of the lysosomal membrane. J Cell Biol. 1985;100:1839-1847.
42. Chen WF, Murphy TL, Willingham MC, Pastan I, August JT. Identification of two lysosomal membrane glycoproteins. J Cell Biol. 1985;101:85-95.
43. Chen JW, Cha Y, Yuksel KU, Gracy RW, August JT. Isolation and sequencing of a cDN A clone encoding lysosomal. J Biol Chem. 1988;263:8754-8758.
44. Fukuda M, Viitala J, Maltesen J, Carlsson R. Cloning of cDNAs encoding human lysosomal membrane glycoproteins h-lamp-1 and h-lamp-2. J Biol Chem. 1988;263:18920-19928.
45. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
46. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413-417.
47. Levy R, Warnke R, Dorfman RF, Haimovich J. The monoclonality of human B-cell lymphomas. J Exp Med. 1977;145:1014-1028.
48. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465-472.
49. Engelmayer J, Larsson M, Subklewe M, et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol. 1999;163:6762-6768.
50. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res. 2003;63:3688-3694.
51. Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163-2173.
52. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
53. Cheson BD. Rituximab: clinical development and future directions. Expert Opin Biol Ther. 2002;2:97-110.
54. Stevenson FK. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev. 1995;145:211-228.
55. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood. 2001;97:1370-1377.
56. Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62:5845-5852.
57. Heslop H, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Rev Hematol. 2003;:331-349.
58. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994;24:605-610.
59. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A. 2000;97:2697-2702.
60. Syrengelas AD, Levy FI. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol. 1999;162:4790-4795.
61. Rowell J, Ruff A, Guarnieri FG, et al. Lysosomal-associated-membrane- protein-1 mediated targeting of the HIV envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J Immunol. 1995;155:1818-1828.
62. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and Class II molecules. J Immunol. 2004;172:6649-6657.
63. + T lymphocytes. Nature. 2003;421:852-855.
64. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300:337-339.
65. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
66. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A. 1996;93:10972-10977.